Objectives: To assess alterations in the composition of peripheral immune cells in acute progressive multifocal leukoencephalopathy (PML). 
Latent infection with the human polyomavirus John Cunningham virus (JCV) is common in healthy individuals. Under circumstances of reduced immunocompetence within the CNS, JCV, which was kept in a quiescent state, is reactivated and causes progressive multifocal leukoencephalopathy (PML). 1 PML is a lytic infection of the brain that often leads to severe neurologic deficits or death. The immunologic characteristics that predispose to the development of PML are poorly defined. 2 HIV infection accounts for about 85% of all PML cases, 1 and up to 5% of patients with AIDS develop PML. 3 In patients with HIV infection, PML typically develops before initiation of antiretroviral therapy, at a time when CD4 helper T cell numbers are low and their function is impaired. PML also develops in 3.7-5.2 in 1,000 patients with relapsing-remitting multiple sclerosis treated for more than 24 months with the VLA-4 antibody natalizumab, which prevents lymphocytes from entering the CNS. In addition, PML has been reported in patients treated with fumaric acid for psoriasis who were lymphopenic for at least several months. 4 These combined observations indicate that persistent alterations in lymphocyte populations or their ability to enter the brain predispose to PML.
Herein, we provide direct evidence that a reduced frequency of peripheral central memory CD4 T cells is associated with the development of PML.
METHODS Standard protocol approvals, registrations, and patient consents. Patients were recruited at the Department of Neurology, University of Tübingen, Germany. All patients gave written informed consent for the provision of blood for the purpose of this research. The protocol under which these samples were obtained was approved by the ethics committee of the University of Tübingen, Germany. Baseline characteristics of the patients are depicted in the table.
Flow cytometric analysis. White blood cell counts were determined by routine testing at the central laboratory of our hospital. Flow cytometric analysis was performed with fresh whole blood specimens after staining with fluorochrome-labeled antibodies. The following antibodies were used: anti-human CD3-APC (1/100) clone UCHT1, anti-human CD4-FITC (1/100) clone SK3, antihuman CD8-PerCP (1/100) clone SK1, anti-human CD19-FITC (1/100) clone HIB19, anti-human CD27-PE (1/50) clone L128, anti-human CD38-APC (1/50) clone HIT2, anti-human CD56-PE (1/50) clone B159, anti-human CD197(CCR7)-PE (1/50) clone 3D12, all from BD Biosciences, and anti-human CD45RA-APC (1/50) clone HI100 from BioLegend. As a reference, these analyses were performed in 10 healthy controls. The mean age of healthy controls was 45 years. Absolute numbers of CD4 and CD8 T cells were calculated by multiplying lymphocyte numbers obtained from the white blood cell count with the frequency of CD4 and CD8 cells in flow cytometric analysis.
Quantitative JCV-PCR. JCV copy numbers were determined by quantitative PCR at the Institute for Virology, Heinrich Heine University, Düsseldorf, Germany. This assay is able to detect less then 10 viral copies/mL CSF.
Statistical analysis. Statistical analysis was performed by unpaired t test using SPSS 22 (IBM Corp., Armonk, NY).
RESULTS Patient characteristics. Three female and 2 male patients between 39 and 56 years of age were recruited at our institution at the initial presentation of PML between 2012 and 2015 (table). Two patients had HIV-associated PML, 2 patients were on treatment with fumaric acid (Fumaderm) for psoriasis for more than 6 months, and one patient with relapsing-remitting multiple sclerosis was on natalizumab for more than 24 months. PML outcome was related to the JCV copy numbers within the CSF at the time of PML diagnosis. In one patient with negative JCV-PCR, PML diagnosis was established by brain biopsy. This patient was completely free of neurologic deficits after resolution of PML. An immune reconstitution inflammatory syndrome (IRIS) developed in both patients with HIV-PML following initiation of combined antiretroviral therapy and in the natalizumab-treated patient with multiple sclerosis following plasma exchange. IRIS was characterized by the development of new neurologic symptoms and new contrast-enhancing lesions on cerebral MRI. Two patients with less than 500 JCV copies per mL CSF had only moderate residual symptoms and 2 patients who displayed .10,000 copies of the JCV DNA per mL of CSF died of PML within 44 and 61 days, respectively. All patients had reduced lymphocyte numbers at the initial diagnosis of PML (table) . DISCUSSION Herein, we provide data indicating that alterations in the composition of peripheral CD4 helper T cell subpopulations are associated with development of PML. CD4 T cells have a pivotal role in the defense against viral infections as has been shown in numerous human diseases including HIV, hepatitis C virus, and JCV. [5] [6] [7] [8] The development of PML is known to be associated with low total numbers of CD4 T cells in patients with late-stage HIV infections and patients with idiopathic CD4 T cell lymphopenia. 9 Our patients with PML did not display any significant alterations in the frequencies of naive, central memory and effector memory CD8 T cells, B lymphocyte populations, and natural killer cells. In contrast, the proportions of CD4 central memory and naive T cells were highly significantly decreased and the proportion of effector memory CD4 T cells was increased. Central memory T cells express the chemokine receptor CRR7 and CD62L and recirculate through secondary lymphoid organs. Effector memory CD4 T cells do not express CCR7 and CD62L, molecules required for entry into lymph nodes, but express chemokine receptors such as CCR5, which direct their migration to the sites of inflammation. They are preferentially located within nonlymphoid tissues or remain within the blood and rapidly exhibit effector functions after a new antigen encounter. 10, 11 The fact that the proportion of CD4 effector memory T cells was high in the peripheral blood of patients with PML thus indicates that a large proportion of peripheral CD4 T cells is actively engaged in viral defense. This is consistent with the previously observed prominent infiltration of CD4 T cells into inflammatory CNS lesions in PML 12 and further supports the central role of CD4 rather than CD8 T cells in immune defense against JCV.
Before the diagnosis of PML, 2 patients had been on immunomodulatory treatment with fumaric acid and one patient with natalizumab. These treatments are known to induce alterations in peripheral immune cells and may thus have influenced our results. Dimethyl fumarate has been shown to both reduce the frequency of lymphocytes in peripheral blood and to disproportionally reduce the frequency of CD8 T cells, 13 while natalizumab increases peripheral lymphocyte counts and the proportion of peripheral B lymphocytes. 14 The fact that the reduction of naive and central memory CD4 T cells was partially restored in patient 2 after resolution of PML and not in patient 1 who displayed a fatal course of PML may further indicate that the frequencies of these cells negatively correlate to PML disease activity. Collectively, these observations are in line with previous reports that found reduced frequencies of CD62L-expressing CD4 T cells in natalizumab-treated patients with relapsing-remitting multiple sclerosis who developed PML. 15 In our cohort, the frequency of central memory CD4 T cells was reduced in patients with HIVassociated PML as well as in patients who developed PML under immunomodulatory treatment. This further supports the notion that the reduced frequency of central memory CD4 T cells represents a state of the immune system with reduced immunocompetence against JCV. Furthermore, these data indicate that additional in-depth analysis of the role of CD4 helper T cell populations during the course of PML could provide important insights into the immune conditions that predispose to this disease. Reconstitution of CD4 T cells in longitudinal analysis might be a predictor for clinical outcome.
Obviously, this investigation is limited by the small number of patients, by the different conditions and medications under which PML developed, and the different courses of disease (i.e., with and without development of IRIS). If confirmed, the observed alterations in CD4 T cell subpopulations could provide new insights into the pathogenesis of PML and may ultimately represent a biomarker for PML disease activity or to detect patients at risk of PML development. This would be urgently needed as JCV infections of the nervous system including PML, JCV meningitis, 16 and cerebellar granule cell neuronopathy 17 become more clinically prominent. Neurology: Neuroimmunology & Neuroinflammation
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